MedTrace Logo

Postherpetic Neuralgia After Herpes Zoster and Incident Dementia Risk

NCT07399288 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68786

Last updated 2026-02-11

No results posted yet for this study

Summary

This retrospective observational cohort study uses de-identified electronic health record data from the TriNetX Global Collaborative Network to evaluate whether postherpetic neuralgia after herpes zoster is associated with an increased risk of incident dementia. Adults aged 40 to 120 years with incident herpes zoster between 1 October 2015 and 31 December 2024 are identified using diagnostic codes. Postherpetic neuralgia is defined by International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes B02.22 or B02.29 recorded between 90 and 365 days after the index herpes zoster date, and comparators have no such codes within 365 days after index. The primary analysis uses 1:1 propensity score matching and a 365-day landmark design, including only individuals alive and free of dementia at the landmark. Time-to-event analyses estimate hazard ratios for incident dementia and related outcomes.

Conditions

  • Herpes Zoster
  • Dementia
  • Postherpetic Neuralgia (PHN)

Interventions

OTHER

Exposure: postherpetic neuralgia

This is an observational study and no treatment is assigned by the investigators. The intervention of interest is exposure status defined by recorded diagnoses of postherpetic neuralgia after herpes zoster, based on ICD-10-CM codes B02.22 or B02.29 within 90 to 365 days after the index herpes zoster date.

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • En-Bo Wu, MD · China Medical University Hospital

Eligibility

Min Age
40 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07399288 on ClinicalTrials.gov